---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000051"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:17:45.010211+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Partner Verona Pharma gets FDA approval for Ohtuvayre (COPD); Ligand earns $5.8M milestone, $13.8M at launch

## Summary
- FDA approved Ohtuvayre (ensifentrine) for maintenance treatment of COPD in adults; first novel inhaled mechanism in over 20 years.
- Ligand earned a $5.8 million milestone payment; additional $13.8 million due upon commercial launch expected in Q3 2024.
- Ligand is entitled to a low single-digit royalty on potential worldwide net sales of Ohtuvayre; COPD market is multi-billion dollar.
- Verona Pharma is responsible for commercialization; Ligand relies on Verona for successful launch and sales.
- Approval triggers immediate milestone and sets stage for further payments and ongoing royalties.

## SEC filing metadata
- accession: 0000886163-24-000051
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000051/0000886163-24-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000051/lgnd-20240627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000051
- JSON: https://secwatch.observer/filing/0000886163-24-000051.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.